Have you missed the webinar? Do you want to re-visit it?
Yes, I want to watch the recording, but do not have an account created yet.
I already have my account created. Take me to the recordings please.
Expanded hemodialysis is a new therapy starting to emerge in Europe. To address this trend, we invited Professor Claudio Ronco and Professor Raymond Vanholder on the 18th of April to discuss about ‘Expanded HD, where do we stand today?’.
Professor Ronco is a Full Professor of Nephrology at the University of Padova, and the Director of the Department of Nephrology and the International Renal Research Institute in Vicenza, Italy. He has authored nearly 1,400 articles with more than 100,000 citations. He is also the Editor-in-Chief of the journals “Blood Purification”, and “Contributions to Nephrology”, as well as Editor Emeritus of "International Journal of Artificial Organs".
During the symposium, Professor Ronco delved into the impact of membrane innovations on dialysis techniques. Expanded hemodialysis is recognized as a new class of therapy linked to a particular type of membrane called medium cut-off or super high flux membranes. These membranes are distinguished from regular high flux membranes due to bigger pore size, and a narrow distribution of the pore size. This technology allows the dialysis to be more efficient by removing the higher middle toxins in regular HD settings. Our product, Elisio HX – a medium cut-off dialyzer – is part of this new category.
Our other distinguished speaker, Professor Raymond Vanholder was the Founding President of the Belgian Society of Nephrology. Plus, he also founded the European Uremic Toxin Work Group - which continuously updates the classification of all the known uremic toxins and translates that knowledge into clinical nephrological practice. With more than 900 articles, he has been on the editorial board of several journals such as "Nature Reviews in Nephrology", "NDT", and "Toxins".
Looking at things from the clinical perspective, Professor Vanholder explored the impact of the membranes on the removal of higher middle molecules and the survival of patients. These molecules have clear links with patients’ co-morbidities such as inflammation and cardiovascular diseases. In Japan, medium cut off dialyzers such as Elisio HX have already been in use for a longer time, and large studies performed in a prospective design, on over more than 200,000 patients, clearly show an increased survival in patients treated with class V or medium cut-off dialyzers*1. As Professor Vanholder said, "With Elisio HX in expanded HD, patients receiving conventional hemodialysis will have the benefits of online HDF without a need for an optimal vascular access or for high volumes of water."
We were delighted to have more than 200 participants attending the event. What's more, they had the opportunity to ask questions in a live Q&A session with Professor Vanholder.
Stay connected with us for a new seminar on another dialyzer in our portfolio. Revealing soon!
